Author

Nicole G. Lipitz

Institution: Syneos Health (United States)

Observed institutions: Syneos Health (United States), Flatiron Health (United States)

OpenAlex ID: A5060102863

Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set

2019 · Sandra D. Griffith, Rebecca A. Miksad, et al. · JCO Clinical Cancer Informatics · 111

Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials

2024 · Rish K. Pai, Geert D’Haens, et al. · Expert Review of Gastroenterology & Hepatology · 29

The Real-World Frequency of 24-Hour Urine Protein Electrophoresis (UPEP), Serum Free Light Chain (SFLC), and Serum Protein Electrophoresis (SPEP) Testing in Patients with Multiple Myeloma (MM)

2018 · Rebekah B. Foster, Nicole G. Lipitz, et al. · Blood · 8

Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM)

2018 · Kathleen Maignan, Daniel Backenroth, et al. · Blood · 1

Works count: 4

Citation count: 149

H-index: 3

I10-index: 2